The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Instititial Lung Diseases: Subgroup with Autoimmune Diseases*
Pneumologie | March 31, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available
10.1055/s-0039-3403189